Completed PHASE2 INTERVENTIONAL NCT00138840

Study of STA-5326 Mesylate in Patients With Moderate to Severe Crohn's Disease

A Randomized, Double-Blind, Placebo-Controlled Clinical Study of the Oral IL-12/23 Inhibitor, STA-5326 Mesylate, for the Induction of Clinical Response in Patients With Crohn's Disease

Sponsor: Synta Pharmaceuticals Corp.

Conditions Crohn's Disease

Interventions STA-5326 mesylate

Updated 6 times since 2017 Last updated: Dec 3, 2008 Started: Aug 31, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Crohn's Disease and is currently completed. Synta Pharmaceuticals Corp. leads this study, which shows 6 recorded versions since 2005 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Aug 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Synta Pharmaceuticals Corp.

Data source: Synta Pharmaceuticals Corp.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Anaheim, United States , Asheville, United States , Atlanta, United States , Austin, United States , Boston, United States , Calgary, Canada , Cedar Knolls, United States , Charlotte, United States , Chevy Chase, United States , Christiansburg, United States and 24 more locations